Last reviewed · How we verify
Iron Isomaltoside 1000, ferric derisomaltose
Iron Isomaltoside 1000, ferric derisomaltose is a Iron replacement agent Small molecule drug developed by Saskatchewan Health Authority - Regina Area. It is currently in Phase 3 development for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy. Also known as: Monoferric DIN 22477777.
Iron isomaltoside 1000 is an iron-carbohydrate complex that delivers ferric iron to bind transferrin and replenish iron stores in patients with iron deficiency.
Iron isomaltoside 1000 is an iron-carbohydrate complex that delivers ferric iron to bind transferrin and replenish iron stores in patients with iron deficiency. Used for Iron deficiency anemia in patients with chronic kidney disease, Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy.
At a glance
| Generic name | Iron Isomaltoside 1000, ferric derisomaltose |
|---|---|
| Also known as | Monoferric DIN 22477777 |
| Sponsor | Saskatchewan Health Authority - Regina Area |
| Drug class | Iron replacement agent |
| Target | Transferrin (iron transport protein) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
The drug consists of ferric iron complexed with isomaltoside, a carbohydrate polymer that protects the iron and facilitates its absorption and transport. Once administered, the iron is released and binds to transferrin in the bloodstream for transport to bone marrow and other tissues, where it is incorporated into hemoglobin and other iron-dependent proteins to treat iron deficiency anemia.
Approved indications
- Iron deficiency anemia in patients with chronic kidney disease
- Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy
Common side effects
- Injection site reactions
- Headache
- Nausea
- Dizziness
- Hypophosphatemia
Key clinical trials
- Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study (PHASE3)
- Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency. (NA)
- Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy (PHASE3)
- Neuroimaging Ancillary Study
- Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial (PHASE4)
- Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer (PHASE3)
- RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study
- The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron Isomaltoside 1000, ferric derisomaltose CI brief — competitive landscape report
- Iron Isomaltoside 1000, ferric derisomaltose updates RSS · CI watch RSS
- Saskatchewan Health Authority - Regina Area portfolio CI
Frequently asked questions about Iron Isomaltoside 1000, ferric derisomaltose
What is Iron Isomaltoside 1000, ferric derisomaltose?
How does Iron Isomaltoside 1000, ferric derisomaltose work?
What is Iron Isomaltoside 1000, ferric derisomaltose used for?
Who makes Iron Isomaltoside 1000, ferric derisomaltose?
Is Iron Isomaltoside 1000, ferric derisomaltose also known as anything else?
What drug class is Iron Isomaltoside 1000, ferric derisomaltose in?
What development phase is Iron Isomaltoside 1000, ferric derisomaltose in?
What are the side effects of Iron Isomaltoside 1000, ferric derisomaltose?
What does Iron Isomaltoside 1000, ferric derisomaltose target?
Related
- Drug class: All Iron replacement agent drugs
- Target: All drugs targeting Transferrin (iron transport protein)
- Manufacturer: Saskatchewan Health Authority - Regina Area — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Iron deficiency anemia in patients with chronic kidney disease
- Indication: Drugs for Iron deficiency anemia in patients intolerant to or unresponsive to oral iron therapy
- Also known as: Monoferric DIN 22477777
- Compare: Iron Isomaltoside 1000, ferric derisomaltose vs similar drugs
- Pricing: Iron Isomaltoside 1000, ferric derisomaltose cost, discount & access